SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Summary

To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.

Eligibility

Patients with T2D

Inclusion Criteria:

* Ages 30-75
* BMI (Body Mass Index) 21-45 kg/m2
* HbA1c = 7.0-11%
* eGFR (estimated glomerular filtration rate)\> 60 ml/min/1.73m2
* Blood Pressure (BP)≤160/90 mmHg
* Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH/T4 (thyroid/thyroxine hormone), EKG (electrocardiogram), and urinalysis (UA)
* Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program
* Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas/Metformin (Sulfo/MET)
* Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment.
* Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment.
* SGLT2 inhibitors must be discontinued at least two months prior to study enrollment.
* Statin therapy is permissible if the dose has been stable for at least 3 months

EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation in this study:

* Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded.
* Patients taking medications other than Sulfonylureas/Metformin (SU/MET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \*
* Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \< 60 are excluded
* Women of childbearing potential are excluded unless they are taking/using appropriate contractive medications/devices \* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor.

If their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%.

HbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase.

After two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes — Karolinska Institutet
• EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease — National Taiwan University Hospital
• Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus — Medanta, The Medicity, India
• Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia — University Hospital, Basel, Switzerland
• Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease — National Taiwan University Hospital
• To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults — Hyundai Pharm
• SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan — The University of Texas Health Science Center at San Antonio
• SGLT2i, Hepatic Glucose Production, and SNS — The University of Texas Health Science Center at San Antonio

Browse More Trials